You are using an outdated browser. Please upgrade your browser to improve your experience and security.

INDICATION
LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN).

Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.

Updated 2024 ACR Guideline for the Screening, Treatment, and Management of LN
FULL ACR GUIDELINE

Get Started With LUPKYNIS

Aurinia Alliance® Provides a Dedicated Support Team for Your Patients and Your Office

RX icon

Patient Start Form is submitted via fax or through ePrescribe. Download here

Nurse icon

Nurse Case Manager supports your patients throughout their treatment with LUPKYNIS

Check icon

Aurinia Alliance completes a benefit investigation. Call 1-833-287-4642 for enrollment inquires

Pharmacy icon

Our Specialty Pharmacy partners will apply co-pay savings and ship directly to your patients

Aurinia Alliance Provides Support for Your Patients on LUPKYNIS

Support Throughout the Treatment Journey

Brian, a real LUPKYNIS patient

<$10

Low Out-of-Pocket Cost

97% of the time, patients have paid less than $10 out of pocket for LUPKYNISa

77%

of patients are approved for LUPKYNIS at prior authorization

Start your patients now by e-prescribing LUPKYNIS to PharmaCord Pharmacy.

aPatients on commercial insurance, Medicaid, or Medicare from January 2023 to June 2024.

EXPLORE ADDITIONAL RESOURCES (LINK)

Reference: Aurinia Pharma U.S. Inc. Data on file.

Connect with an Aurinia representative.
Sign up for the latest news, updates, and materials for LUPKYNIS.

GET CONNECTED
Get one-on-one support

IMPORTANT SAFETY INFORMATION

BOXED WARNING: MALIGNANCIES AND SERIOUS INFECTIONS

LUPKYNIS increases the risk of serious infections and malignancies that may result in hospitalization or death. See full Prescribing Information for complete BOXED WARNING.

CONTRAINDICATIONS

  • DO NOT use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin).
  • DO NOT use LUPKYNIS if a patient has a history of serious hypersensitivity reactions, including anaphylaxis, to LUPKYNIS or any of its components.

WARNINGS AND PRECAUTIONS

  • Nephrotoxicity may occur. Monitor eGFR and adjust dose as needed.
  • Hypertension is common. Monitor blood pressure. May require antihypertensive therapy; watch for possibility of drug interactions with some antihypertensives.
  • Neurotoxicity: Monitor for neurologic symptoms including risk of posterior reversible encephalopathy syndrome (PRES).
  • Hyperkalemia: Monitor potassium, especially with concomitant agents associated with hyperkalemia.
  • QT Prolongation: Monitor ECG and electrolytes in high-risk patients.
  • Hypersensitivity Reactions (Including Anaphylaxis and Angioedema): Monitor and discontinue if reaction occurs.
  • Pure Red Cell Aplasia: Monitor and consider discontinuation if diagnosed.
  • Immunizations: Avoid live vaccines.
  • Lymphomas and Other Cancers: Immunosuppressants increase the risk of lymphomas and other cancers, especially of the skin. Monitor for skin changes and advise sun protection and avoidance of artificial UV light.

ADVERSE REACTIONS

The most common adverse reactions (≥3% and ≥2% against placebo) include decreased GFR, hypertension, diarrhea, headache, anemia, cough, urinary tract infection, abdominal pain upper, dyspepsia, alopecia, renal impairment, abdominal pain, mouth ulceration, fatigue, tremor, acute kidney injury, and decreased appetite. Nausea and vomiting have been reported during post-approval use.

SPECIFIC POPULATIONS

Pregnancy: Inform female patients of the potential risk to a fetus and to avoid use of LUPKYNIS during pregnancy.

Indication

LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN).

Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.

Please see full Prescribing Information, including BOXED WARNING, and Medication Guide for additional Important Safety Information about LUPKYNIS.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: MALIGNANCIES AND SERIOUS INFECTIONS

LUPKYNIS increases the risk of serious infections and malignancies that may result in hospitalization or death. See full Prescribing Information for complete BOXED WARNING.

CONTRAINDICATIONS:

  • DO NOT use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin).
  • DO NOT use LUPKYNIS if a patient has a history of serious hypersensitivity reactions, including anaphylaxis, to LUPKYNIS or any of its components.

WARNINGS AND PRECAUTIONS

  • Nephrotoxicity may occur. Monitor eGFR and adjust dose as needed.
  • Hypertension is common. Monitor blood pressure. May require antihypertensive therapy; watch for possibility of drug interactions with some antihypertensives.
  • Neurotoxicity: Monitor for neurologic symptoms including risk of posterior reversible encephalopathy syndrome (PRES).
  • Hyperkalemia: Monitor potassium, especially with concomitant agents associated with hyperkalemia.
  • QT Prolongation: Monitor ECG and electrolytes in high-risk patients.
  • Hypersensitivity Reactions (Including Anaphylaxis and Angioedema): Monitor and discontinue if reaction occurs.
  • Pure Red Cell Aplasia: Monitor and consider discontinuation if diagnosed.
  • Immunizations: Avoid live vaccines.
  • Lymphomas and Other Cancers: Immunosuppressants increase the risk of lymphomas and other cancers, especially of the skin. Monitor for skin changes and advise sun protection and avoidance of artificial UV light.

ADVERSE REACTIONS

The most common adverse reactions (≥3% and ≥2% against placebo) include decreased GFR, hypertension, diarrhea, headache, anemia, cough, urinary tract infection, abdominal pain upper, dyspepsia, alopecia, renal impairment, abdominal pain, mouth ulceration, fatigue, tremor, acute kidney injury, and decreased appetite. Nausea and vomiting have been reported during post-approval use.

SPECIFIC POPULATIONS

Pregnancy: Inform female patients of the potential risk to a fetus and to avoid use of LUPKYNIS during pregnancy.

Indication

LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN).

Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.

Please see full Prescribing Information, including BOXED WARNING, and Medication Guide for additional Important Safety Information about LUPKYNIS.